Neuroendocrine response to meta-chlorophenylpiperazine and ipsapirone in relation to anxiety and aggression

Psychiatry Research

Volumn 113, Issue 1-2, 2002, Pages 29-40

  Klaassen, Tineke ^a   Riedel, Wim J ^a   Van Praag, Herman M ^a   Menheere, Paul P C A ^b   Griez, Eric ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Affective disorders; Cortisol; Functional approach

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CORTICOTROPIN; HYDROCORTISONE; IPSAPIRONE; PLACEBO; PROLACTIN; SEROTONIN 1A AGONIST; SEROTONIN 2C AGONIST;

ADULT; AGGRESSION; ANGER; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOTROPIN BLOOD LEVEL; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HORMONE RESPONSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RATING SCALE; SIDE EFFECT;

EID: 0037114867     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(02)00250-0     Document Type: Article

References (71)

1. Alper R.H. Evidence for central and peripheral serotonergic control of corticosterone secretion in the conscious rat. Neuroendocrinology. 51:(3):1990;255-260.
2. Apter A., van Praag H.M., Plutchik R., Sevy S., Korn M., Brown S.L. Interrelationships among anxiety, aggression, impulsivity, and mood: a serotonergically linked cluster? Psychiatry Research. 32:1990;191-199.
3. Asberg M., Träskman L., Thorén P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Archives of General Psychiatry. 33:1976;1193-1197.
4. Banki C.M., Molnar G., Vojnik M. Cerebrospinal fluid amine metabolites, tryptophan and clinical parameters in depression. Part 2. Psychopathological symptoms. Journal of Affective Disorders. 3:1981;91-99.
5. Bell R., Hobson H. 5-HT1A receptor influences on rodent social and agonistic behavior: a review and empirical study. Neuroscience and Biobehavioral Reviews. 18:1994;325-338.
6. Benkelfat C., Ellenbogen M.A., Dean P., Palmour R.M., Young S.N. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Archives of General Psychiatry. 51:1994;687-697.
7. Buss A.H., Durkee A. An inventory for measuring different kinds of hostility. Journal of Consulting Psychology. 21:1957;343-349.
8. Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology. 92:1987;14-24.
9. Cleare A.J., Bond A.J. The effect of tryptophan depletion and enhancement on subjective and behavioural aggression in normal male subjects. Psychopharmacology. 118:1995;72-81.
10. Cleare A.J., Forsling M., Bond A.J. Neuroendocrine and hypothermic effects of 5-HT1A receptor stimulation with ipsapirone in healthy men: a placebo-controlled study. International Clinical Psychopharmacology. 13:(1):1998;23-32.
11. Coccaro E.F. Central serotonin and impulsive aggression. British Journal of Psychiatry. 155:(suppl.8):1989;52-62.
12. Coccaro E.F. Impulsive aggression and central serotonergic system function in humans: an example of a dimensional brain-behavior relationship. International Clinical Psychopharmacology. 7:1992;3-12.
13. Coccaro E.F., Kavoussi R.J., Hauger R.L. Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. International Clinical Psychopharmacology. 10:1995;177-179.
14. Coccaro E.F., Berman M.E., Kavoussi R.J., Hauger R.L. Relationship of prolactin response to d-fenfluramine to behavioral and questionnaire assessments of aggression in personality-disordered men. Biological Psychiatry. 40:(3):1996;157-164.
15. Coccaro E.F., Kavoussi R.J., Cooper T.B., Hauger R.L. Central serotonin activity and aggression: inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. American Journal of Psychiatry. 154:(10):1997;1430-1435.
16. Coryell W., Endicott J., Winokur G. Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology. American Journal of Psychiatry. 149:1992;100-107.
17. Di-Sciullo A., Bluet-Pajot M.T., Mounier F., Oliver C., Schmidt B., Kordon C. Changes in anterior pituitary hormone levels after serotonin 1A receptor stimulation. Endocrinology. 127:(2):1990;567-572.
18. Endicott J., Spitzer R.L. Schedule for Affective Disorders and Schizophrenia. 1978;Biometrics Research, New York State Psychiatric Institute, New York.
19. Galard R., Gallart J.M., Catalan R., Schwartz S., Arguello J.M., Castellanos J.M. Salivary cortisol levels and their correlation with plasma ACTH levels in depressed patients before and after the DST. American Journal of Psychiatry. 148:(4):1991;505-508.
20. Germine M., Goddard A.W., Woods S.W., Charney D.S., Heninger G.R. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biological Psychiatry. 32:1992;457-461.
21. Glennon R.A., Ismael A., McCarthy B.J., Peroutka S.J. Binding of arylpiperazines to 5-HT3 receptors. Results of a structure-affinity study. European Journal of Pharmacology. 168:1989;387-392.
22. Goddard A.W., Charney D.S., Germine M., Woods S.W., Heninger G.R., Krystal J.H., Goodman W.K., Price L.H. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biological Psychiatry. 38:1995;74-85.
23. Gotlib I.H., McCabe S.B. An information-processing approach to the study of cognitive functioning in depression. Progress in Experimental Personality and Psychopathology Research. 15:1992;131-161.
24. Hamik A., Peroutka S.J. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biological Psychiatry. 25:1989;569-575.
25. Handelsman L., Kahn R.S., Sturiano C., Rinaldi P.J., Gabriel S., Schmeidler J.P., Bernstein D.P., Siever L., Cooper T.B. Hostility is associated with a heightened prolactin response to meta-chlorophenylpiperazine in abstinent cocaine addicts. Psychiatry Research. 80:1998;1-12.
26. Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. Journal of Receptor Research. 8:1988;59-81.
27. Kahn R.S., Wetzler S., van Praag H.M., Asnis G.M. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Research. 25:1988a;101-104.
28. Kahn R.S., Wetzler S., van Praag H.M., Asnis G.M. Neuroendocrine evidence for 5-HT receptor hypersensitivity in patients with panic disorder. Psychopharmacology. 96:1988b;360-364.
29. Kahn R.S., Wetzler S., Asnis G.M., Kling M.A., Suckow R.F., van Praag H.M. Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects. Psychiatry Research. 37:1991;25-34.
30. Kahn R.S., Trestman R., Lawlor B.A., Gabriel S., Davidson M., Siever L. Effects of ipsapirone in healthy subjects: a dose-response study. Psychopharmacology. 114:(1):1994;155-160.
31. Kennett G.A., Pittaway K., Blackburn T.P. Evidence that 5-HT2c receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology (Berl). 114:1994;90-96.
32. Klaassen T., Ho Pian K., Westenberg H.G.M., Den Boer J.A., van Praag H.M. Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazine. Psychiatry Research. 79:1998a;207-212.
33. Klaassen T., Klumperbeek J., Deutz N.E.P., van Praag H.M., Griez E. Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge. Psychiatry Research. 77:1998b;167-174.
34. Korf J., van Praag H.M. Endogenous depressions with and without disturbances in the 5-hydroxytryptamine metabolism: a biochemical classification? Psychopharmacologia. 19:1971;148-152.
35. Leonard B.E. Serotonin receptors and their function in sleep, anxiety disorders and depression. Psychotherapy and Psychosomatics. 65:1996;66-75.
36. Mahmood T., Silverstone T. Serotonin and bipolar disorder. Journal of Affective Disorders. 66:2001;1-11.
37. Masand P.S., Gupta S. Selective serotonin-reuptake inhibitors: an update. Harvard Review of Psychiatry. 7:1999;69-84.
38. Moeller F.G. Ipsapirone neuroendocrine challenge: relationship to aggression as measured in the human laboratory. Psychiatry Research. 81:1998;31-38.
39. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry. 134:1979;382-389.
40. Mook J., van der Ploeg H.M., Kleijn W.C. Anxiety, anger and depression: relationships at the trait level. Anxiety Research. 3:1990;17-31.
41. Moss H.B., Yao J.K., Panzak G.L. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biological Psychiatry. 28:1990;325-338.
42. Netter P., Hennig J., Rohrmann S. Psychobiological differences between the aggression and psychoticism dimension. Pharmacopsychiatry. 32:1999;5-12.
43. Nutt D., Lawson C. Panic attacks. A neurochemical overview of models and mechanisms. British Journal of Psychiatry. 160:1992;165-178.
44. Olivier B., Moss J. Serotonin receptor subtypes and aggressive behaviour. Neuropsychopharmacology. 10:1994;944s.
45. Pabis D.J., Stanislav S.W. Pharmacotherapy of aggressive behavior. Annals of Pharmacotherapy. 30:1996;278-287.
46. Raap D.K., van de Kar L.D. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sciences. 65:1999;1217-1235.
47. Riedel, W.J., Klaassen, T., Griez, E., Honig, A., Menheere, P.P.C.A., van Praag, H.M., 2002. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: Evidence for receptor-specific serotonergic dysregulation in depressed mood. Neuropsychopharmacology, in press.
48. Roerig J.L. Diagnosis and management of generalized anxiety disorder. Journal of the American Pharmaceutical Association (Washington). 39:(6):1999;811-821.
49. Rydin E., Schalling D., Åsberg M. Rorschach ratings in depressed and suicidal patients with low levels of 5-hydroxyindoleacetic acid in cerebrospinal fluid. Psychiatry Research. 7:1982;229-243.
50. Salzman C., Wolfson A.N., Schatzberg A., Looper J., Henke R., Albanese M., Schwartz J., Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology. 15:1995;23-29.
51. Sanchez C., Hyttel J. Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors. European Journal of Pharmacology. 264:1994;241-247.
52. Schreiber R., De Vry J. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat. European Journal of Pharmacology. 249:1993;341-351.
53. Schruers K., Klaassen T., Pols H., Overbeek T., Deutz N.E., Griez E. Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients. Psychiatry Research. 93:2000;179-187.
54. Spielberger C.D. Manual for the State-Trait Anxiety Inventory STAI-Form Y. 1983;Consulting Psychologists Press, Palo Alto, CA.
55. Spielberger C.D., Jacobs G., Russel S., Crane S.R. Assessment of Anger: the State-Trait Anger Scale. Butcher J.N., Spielberger C.D. Advances in Personality Assessment. 1983;159-187 Lawrence Erlbaum, Hillsdale, NJ.
56. Stahl S.M., Gastpar M., Keppel Hesselink J.M., Traber J. Serotonin 1A Receptors. 1992;Raven Press, New York.
57. Stokes, P.E., 1995. The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. European Neuropsychopharmacology suppl. 77-82.
58. Stolk L.M.L., Groothuijsen H., Hoogtanders K. A semi-automated sensitive HPLC method for detemination of m-chlorophenylpiperazine in plasma. Therapeutic Drug Monitoring. 19:1997;S588.
59. Tuinier S., Verhoeven W.M., van Praag H.M. Cerebrospinal fluid 5-hydroxyindolacetic acid and aggression: a critical reappraisal of the clinical data. International Clinical Psychopharmacology. 10:1995;147-156.
60. van de Kar L.D., Lorens S.A., Urban J.H., Bethea C.L. Effect of selective serotonin (5-HT) agonists and 5-HT2 antagonist on prolactin secretion. Neuropharmacology. 28:(3):1989;299-305.
61. van der Ploeg, H.M., Defares, P.B., Spielberger, C.D., 1980. Handleiding bij de Zelf Beoordelings Vragenlijst, ZBV (Manual for the Dutch Adaptation of the STAI-Y). Swets & Zeitlinger, Swets & Zeitlinger.
62. van der Ploeg, H.M., Defares, P.B., Spielberger, C.D., 1982. Handleiding bij de Zelf Analyse Vragenlijst, ZAV (Manual for the Dutch Adaptation of the STAS). Swets & Zeitlinger, Swets & Zeitlinger.
63. van Praag H.M. Affective disorders and aggression disorders: evidence for a common biological mechanism. Suicide and Life Threatening Behaviors. 16:1986;103-132.
64. van Praag H.M. 5-HT-related, anxiety- and/or aggression-driven depression. International Clinical Psychopharmacology. 9:1994;5S-6S.
65. van Praag H.M., Asnis G.M., Kahn R.S., Brown S.L., Korn M., Friedman J.M., Wetzler S. Monoamines and abnormal behaviour. A multi-aminergic perspective. British Journal of Psychiatry. 157:1990;723-734.
66. van Praag H.M., Kahn R.S., Asnis G.M., Wetzler S., Brown S.L., Bleich A., Korn M.L. Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. Journal of Affective Disorders. 13:1987;1-8.
67. Westenberg H.G., Verhoeven W.M. CSF monoamine metabolites in patients and controls: support for a bimodal distribution in major affective disorders. Acta Psychiatrica Scandinavica. 78:1988;541-549.
68. Wetzler S., Kahn R.S., Asnis G.M., Korn M., van Praag H.M. Serotonin receptor sensitivity and aggression. Psychiatry Research. 37:1991;271-279.
69. Winchel R.M., Stanley M. Self-injurious behavior: a review of the behavior and biology of self-mutilation. American Journal of Psychiatry. 148:1991;306-317.
70. Wing J.K., Babor T., Brugha T., Burke J., Cooper J.E., Giel R., Jablenski A., Regier D., Sartorius N. SCAN, Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry. 47:1990;589-593.
71. Yatham L.N., Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sciences. 53:1993;447-463.